Enhancing Quality...This Annual Report contains financial statements, results of operations, policies, projections, plans, ... tentang tugas, peran, serta fungsi struktural organisasi

Laporan Tahunan

annuaL reporT

2018E

nh

an

cin

g Q

ua

lity

Pr

ov

idin

g Th

e B

es

T

Ench

ancin

g Qu

ality

,

Prov

idin

g The

BesT

pT KIMIa FarMa (perSero) Tbk

Meni

ngka

tkan

kual

itas,

Meng

hadi

rkan

yan

g te

rbai

k

2

Annual Report 2018 | PT Kimia Farma (Persero) Tbk Enhancing Quality Providing thE BEstMEningkatkan kualitas, MEnghadirkan yang tErBaik PT Kimia Farma (Persero) Tbk | Laporan Tahunan 2018

3


Sanggahan dan Batasan Tanggung JawabDisclaimer and Limitation of Liability

Performance Highlights

Management Report

Company Profile

Management Discussion & Analysis

Corporate Governance

Corporate Social Responsibility

Business Support Functions

Sanggahan dan Batasan Tanggung JawabDisclaimer and Limitation of Liability

Laporan Tahunan ini memuat pernyataan kondisi keuangan, hasil operasi, kebijakan, proyeksi, rencana, strategi, serta tujuan PT Kimia Farma (Persero) Tbk yang digolongkan sebagai pernyataan ke depan dalam pelaksanaan perundang-undangan yang berlaku, kecuali hal-hal yang bersifat historis. Pernyataan-pernyataan tersebut memiliki prospek risiko, ketidakpastian, serta dapat mengakibatkan perkembangan aktual secara material berbeda dari yang dilaporkan. Pernyataan-pernyataan prospektif dalam Laporan Tahunan ini dibuat berdasarkan berbagai asumsi mengenai kondisi terkini dan kondisi mendatang serta lingkungan bisnis dimana PT Kimia Farma (Persero) Tbk menjalankan kegiatan usaha. PT Kimia Farma (Persero) Tbk tidak menjamin bahwa dokumen-dokumen yang telah dipastikan keabsahannya akan membawa hasil-hasil tertentu sesuai harapan.

Laporan Tahunan ini memuat kata “Perseroan” ,”KAEF”, “Kimia Farma” atau “Perusahaan” yang didefinisikan sebagai PT Kimia Farma (Persero) Tbk yang menjalankan kegiatan usaha utama dalam bidang layanan kesehatan. Adakalanya kata “kami” digunakan atas dasar kemudahan untuk menyebut PT Kimia Farma (Persero) Tbk secara umum.

This Annual Report contains financial statements, results of operations, policies, projections, plans, strategies, and objectives of PT Kimia Farma (Persero) Tbk which are classified as forward statements in the implementation of laws, except historical matters. These statements have risk prospects, uncertainties, and can result an actual developments that materially different from those reported. Prospective statements in this Annual Report are based on various assumptions regarding current conditions and future conditions and business environment in which PT Kimia Farma (Persero) Tbk conducts business activities. PT Kimia Farma (Persero) Tbk does not guarantee that documents that have been ensured of their validity will bring certain results as expected.

This Annual Report contains the words “Company”, “KAEF”, or “Kimia Farma” defined as PT Kimia Farma (Persero) Tbk that runs the main business activities in the field of health services. Sometimes the pronoun “we” is used on the basis of ease of referring to PT Kimia Farma (Persero) Tbk in general.

4


Tentang Laporan Tahunan pt Kimia Farma (persero) Tbk Tahun 2018About PT Kimia Farma (Persero) Tbk Annual Report of 2018Tentang Laporan Tahunan pt Kimia Farma (persero) Tbk Tahun 2018About PT Kimia Farma (Persero) Tbk Annual Report of 2018

Selamat datang pada Laporan Tahunan 2018 PT Kimia Farma (Persero) Tbk. Tujuan utama penyusunan Laporan Tahunan ini adalah untuk meningkatkan keterbukaan informasi Perseroan kepada otoritas terkait serta menjadi buku tahunan yang turut membangun rasa bangga dan solidaritas di antara insan Kimia Farma.

Laporan Tahunan 2018 PT Kimia Farma (Persero) Tbk menjadi sumber dokumentasi komprehensif yang berisikan informasi kinerja Perseroan dalam setahun. Informasi tersebut memuat dokumentasi lengkap yang menggambarkan profil Perseroan; kinerja operasional, pemasaran, dan keuangan; informasi tentang tugas, peran, serta fungsi struktural organisasi yang menerapkan konsep best practices dan prinsip-prinsip Tata Kelola Perusahaan yang Baik, atau Good Corporate Governance (GCG).

Selain itu, Laporan Tahunan ini juga bertujuan untuk membangun pemahaman dan kepercayaan tentang PT Kimia Farma (Persero) Tbk dengan menyediakan informasi yang tepat, seimbang, dan relevan. Para pemegang saham serta seluruh pemangku kepentingan lainnya dapat memperoleh informasi yang memadai terkait kebijakan yang telah dan akan dilakukan serta kesuksesan pencapaian Perseroan pada tahun 2018.

Laporan Tahunan PT Kimia Farma (Persero) Tbk 2018 disajikan dalam 2 (dua) bahasa, yaitu Bahasa Indonesia dan Bahasa Inggris dalam buku yang berbeda dengan menggunakan jenis dan ukuran huruf yang mudah dibaca dan dicetak dengan kualitas baik.

Laporan Tahunan ini dapat dilihat dam diunduh dalam situs web resmi PT Kimia Farma (Persero) Tbk dengan alamat www.kimiafarma.co.id

Welcome to the 2018 Annual Report of PT Kimia Farma (Persero) Tbk. The main objective of the preparation of this Annual Report is to improve the transparency of the Company’s information to the relevant authorities and become an annual book that builds pride and solidarity among the people of Kimia Farma.

PT Kimia Farma (Persero) Tbk Annual Report of 2018 to be comprehensive document resources that contains Company performance information in a year. This information contains complete documentary that describes company profile; operational, marketing and financial performance; information about duties, roles, and organizational structural functions that apply best practice concepts and principles of Good Corporate Governance (GCG).

In addition, this Annual Report also purposes to build comprehension and trust regarding PT Kimia Farma (Persero) Tbk by providing accurate, balanced, and relevant informations. Shareholders and all other stakeholders can obtain adequate information regarding policies that have been and will be carried out and the success of the Company’s achievements in 2018.

Kimia Farma (Persero) Tbk Annual Report of 2018 is presented in 2 (two) languages, Indonesian and English in different books using types and font sizes that are easy to read and print with good quality.

This Annual Report can be viewed and downloaded on the official website of PT Kimia Farma (Persero) Tbk at www.kimiafarma.co.id.

5


Informasi yang Disajikan dalam Laporan TahunanThe information presented in the Annual Report


Management Report

Company Profile






Referensi dan standar yang digunakan PT Kimia Farma (Persero) Tbk dalam penyusunan Laporan Tahunan ini menggunakan parameter dan kriteria standar yang berlaku di Indonesia, tempat dimana Perseroan melaksanakan kegiatan usahanya. Dengan statusnya sebagai perusahaan terbuka yang memperdagangkan sahamnya kepada publik di Bursa Efek Indonesia, maka penyampaian Laporan Tahunan menggunakan kriteria yang tercantum dalam Peraturan Otoritas Jasa Keuangan No. 29/POJK.04/2016 tentang Laporan Tahunan Emiten atau Perusahaan Publik, dan Surat Edaran Otoritas Jasa Keuangan No. 30/SEOJK.04/2016 tentang Bentuk dan Isi Laporan Tahunan Emiten atau Perusahaan Publik, serta kriteria dalam Annual Report Award (ARA).

Dalam rangka menjalankan best practice pelaksanaan prinsip-prinsip Tata Kelola Perusahaan yang Baik atau Good Corporate Governance (GCG), penyampaian laporan ini juga mengacu pada pedoman praktik tata kelola yang berlaku di lingkup regional ASEAN, yaitu menggunakan parameter ASEAN GCG Scorecard. Perseroan juga menyampaikan beberapa aspek yang merupakan bagian dari pengembangan dan interpretasi kami atas isi Laporan Tahunan. Dengan demikian, PT Kimia Farma (Persero) Tbk mengharapkan Laporan Tahunan ini dapat mendorong peningkatan keterbukaan informasi yang wajar seiring dengan terpenuhinya aspek komposisi dan aspek substansi.

The references and standards that used by PT Kimia Farma (Persero) Tbk in the preparation of this Annual Report is standard parameters and criteria that apply in Indonesia, the place where the Company carries out the business activities. With its status as a public company that trades its shares to public on Indonesia Stock Exchange, the presentation of the Annual Report uses the criteria listed in the Financial Services Authority Regulation No. 29 / POJK.04 / 2016 concerning the Annual Report of Issuers or Public Companies, and the Financial Services Authority Circular No. 30 / SEOJK.04 / 2016 concerning the Form and Content of the Annual Report of Issuers or Public Companies, as well as criteria in the Annual Report Award (ARA).

In order to carry out best practice in implementation of Good Corporate Governance (GCG) priciples, the presentation of this report also refers to the guidelines for governance practices that apply in the ASEAN regional scope, using the ASEAN CG Scorecard parameter. Company also presents several aspects that are part of our development and interpretation of the contents of the Annual Report. Therefore, PT Kimia Farma (Persero) Tbk expects this Annual Report can encourage an increase in fair information disclosure along with the fulfillment of the composition and substance aspects.


Kesinambungan TemaThemes Continuity

Memperkuat Sinergi, Meningkatkan Daya Saing PT Bank Kimia Farma | Laporan Tahunan 2018

6Kesinambungan TemaThemes Continuity

Manajemen Kimia Farma berupaya mewujudkan keunggulan melalui langkah-langkah ef isiensi dan inovasi di seluruh aspek operasional Perseroan.

Kimia Farma’s Management was making the best efforts through the implementation of efficiency and innovative actions in all operational aspects of the Company.

Peningkatan kinerja yang dicapai Kimia Farma di tahun 2016 memberikan tantangan bagi Perseroan untuk terus mempertahankan kinerja yang ada dan berupaya untuk terus meningkat, sehingga Kimia Farma mampu memperoleh keunggulan daya saing secara berkelanjutan.

Performance improvement made by Kimia Farma in 2016 posed a challenge for the Company to continuously maintain the performance and making efforts for another improvement, which will enable Kimia Farma to gain competitive advantages sustainably.

Berdiri pada 1817 sebagai perusahaan industri farmasi pertama di Indonesia, Kimia Farma telah berkembang menjadi perusahaan dengan pelayanan kesehatan (Healthcare) terintegrasi di Indonesia . Bidang usaha Healthcare Kimia Farma didukung oleh kegiatan manufaktur farmasi, riset dan pengembangan, distribusi dan perdagangan, pemasaran, ritel farmasi, serta laboratorium klinik dan klinik kesehatan.

Established in 1817 as the f irst pharmaceutical industry company in Indonesia, Kimia Farma has developed into a company with integrated Healthcare services in Indonesia. Kimia Farma’s Healthcare business is supported by pharmaceutical manufacturing, research and development , market ing, distribution, retail, and clinical laboratories and clinics

Realizing Excellence Through Innovation Mewujudkan Keunggulan Melalui Inovasi

Managing the Challenge of Growth Mengelola Tantangan pertumbuhan

Transforming into aDigital Healthcare Company Transformasi Menuju perusahaan healthcare Berbasis Digital

17

16

15

7


penjelasan TemaTheme Explanation


Management Report

Company Profile





penjelasan TemaTheme Explanation

Peningkatan dan perbaikan adalah salah satu prinsip mendasar bagi siapapun untuk dapat menciptakan nilai tambah bagi peradaban. Demikian pula Kimia Farma yang terus melakukan upaya-upaya perbaikan dan peningkatan di setiap lini dan aspek, agar dapat menghadirkan kualitas produk dan layanannya.

Salah satunya adalah transformasi digital yang diusung sebagai bagian dari perubahan mendasar dalam proses bisnis Kimia Farma. “Digital Farmasi”, demikian konsep yang diusung Kimia Farma, diterapkan agar mampu memperkuat seluruh mata rantai dan ekosistem dalam kelompok usaha, serta pengelolaan organisasi yang akuntabel. Transformasi ini kemudian diterjemahkan ke dalam penguatan kompetensi dan kapasitas insan Kimia Farma agar mampu berjalan beriringan dengan proses perubahan yang terjadi.

Tema laporan tahunan “Enhancing Quality, Providing the Best” atau “Meningkatkan Kualitas, Menghadirkan yang Terbaik” menjadi gambaran proses transformasi tersebut, yang diharapkan akan mampu menciptakan nilai tambah yang berkelanjutan bagi Kimia Farma.

Enhancement and improvement is one of the fundamental principles for anyone to be able to create value- added for civilization. Likewise, Kimia Farma continues to make enhancements and improvements in every line and aspect, in order to deliver the quality of its products and services.

One of them is digital transformation which is carried out as part of a fundamental change in the Kimia Farma business process. “Digital Pharmacy”, according to the concept promoted by Kimia Farma, is applied in order to strengthen all links and ecosystems in business groups, as well as managing accountable organizations. This transformation was then translated into competency and capacity strengthening of Kimia Farma employees in order to walk hand in hand in the process of change.

The theme of the annual report “Enhancing Quality, Providing the Best” is an illustration of the transformation process, which is expected to be able to create sustainable added value for Kimia Farma.

MenIngKaTKan KuaLITaS, MenghaDIrKan yang TerBaIK

Enchancing Quality,Providing The BesT

8


Jejak LangkahMilestone

Perseroan didirikan oleh Pemerintah Hindia Belanda sebagai Perusahaan Industri Farmasi pertama, dengan nama NV Chemicalien Handle Rathkamp & Co..

The Company was established by Dutch East Indies as the first pharmaceutical industry Company, under the name of NV Chemicalien Handle Rathkamp & Co.

Pemerintah Republik Indonesia melakukan peleburan sejumlah perusahaan farmasi menjadi Perusahaan Negara Farmasi (PNF) Bhinneka Kimia Farma. Government of Republic of Indonesia combined some pharmaceutical companies to become Pharmaceutical State Company (PNF) Bhinneka Kimia Farma.

Badan hukum PNF diubah menjadi Perseroan Terbatas sehingga nama perusahaan berubah menjadi PT Kimia Farma (Persero). PNF legal entity changed to Limited Company, so the Company’s name changed o PT Kimia Farma (Persero).

Badan hukum PNF diubah menjadi

Perseroan Terbatas sehingga nama

perusahaan berubah menjadi PT Kimia

Farma (Persero). PNF legal entity

changed to Limited Company, so the

Company’s name changed o PT Kimia

Farma (Persero).

1871

19581971

2001


9




Management Report

Company Profile





PT Kimia Farma (Persero) Tbk menjadi Healthcare Company.

PT Kimia Farma (Persero) Tbk become a Healthcare Company.

PT Kimia Farma (Persero) Tbk menanamkan landasan transformasi untuk menjadi perusahaan Healthcare berbasis digital. PT Kimia Farma (Persero) Tbk started to build a foundation for tansformation towards a Digital Healthcare Company.

Pembentukan Kimia Farma Dawaa, anak usaha baru yang bergerak pada ritel farmasi di Arab Saudi.The establishment of Kimia Farma Dawaa, a new subsidiary engaged in pharmaceutical retail on the Saudi Arabian.

2014

2017

2018

“Sebagai Badan usaha Milik negara

yang bergerak di sektor farmasi, Kimia

Farma memiliki komitmen untuk

dapat mendukung program layanan

kesehatan bagi masyarakat Indonesia.”

“As a State-Owned Enterprise engaged

in the pharmaceutical sector, Kimia Farma has a commitment

to be able to support healthcare programs

for the people of Indonesia.”

10


Sinergi Layanan Kesehatan dari hulu hingga ke hilirHealth Service Synergy from Upstream to DownstreamSinergi Layanan Kesehatan dari hulu hingga ke hilirHealth Service Synergy from Upstream to Downstream

• ManufakturdanMarketingBahanBakuObat

• 75%produkekspor

• WarehousedandistributorProdukKFdanPihak-3

• Terdapat7(tujuh)pabrikyangsaatiniberoperasi

KimiaFarmaSungwunPharmacopia(KFSP)

MaTa ranTaI FarMaSI DarI huLu hIngga Ke hILIrend To end Business pharmaceutical

NationalDistributionCenter(NDC)

PabrikFarmasiPharmaceutical Plant

• Manufacturing and marketing of medicinal raw materials

• 75% of export products

• Warehouse and distributor of KF and 3rd-party products

• There are 7 (tujuh) factories currently operating

• Pengembangandanpenelitian• newproductdanexisting

ResearchandDevelopment

• Development and research• new product and existing

11


Sinergi Layanan Kesehatan dari hulu hingga ke hilirHealth Service Synergy from Upstream to Downstream


Management Report

Company Profile





KimiaFarmaDawaa

• 47Cabang• Perdagangan&DistribusiProdukKFdanProdukPihak-3

• JaringanapotekterluasdanterbesardiIndonesia.

• Memiliki1138outlet• 530KlinikKesehatan• 10Optik

KimiaFarmaTrading&Distribution(KFTD)

Pasienpatient

KimiaFarmaApotek(KFA)

• 47 Branches• Trade & Distribution of KF

products and 3-party products • The widest and largest pharmacy network in Indonesia

• has 1138 outlets• 530 health Clinics• 10 optics

• 56Laboratoriumklinik

KimiaFarmaDiagnostika(KFD)

• 56 Diagnostic laboratorium

KimiaFarmaDawaa

34RitelFarmasidanAlatKesehatandiArabSaudi

34 pharmaceutical and Medical Devices retailers in Saudi arabia

“Grup Kimia Farma berupaya menghadirkan produk dan layanan bermutu, melalui sinergi dalam kelompok usaha. Di samping itu, sinergi dalam kelompok usaha akan memperkuat lini bisnis Kimia Farma, dan menjadi fondasi yang kokoh bagi pertumbuhan di masa mendatang.”

“Kimia Farma group strives to deliver quality products and services, through synergies in business groups. In addition, the business group synergies will strengthen the Kimia Farma business line, and become a solid foundation for future growth.”

12


pabrik Farmasi: Menghadirkan produk Bermutu dan BerkualitasPharmaceutical Plant: Presenting High Quality Productpabrik Farmasi: Menghadirkan produk Bermutu dan BerkualitasPharmaceutical Plant: Presenting High Quality Product

MeNINGKATKAN KuAlITAS, MeNGHADIRKAN yANG TeRBAIK PT Kimia Farma (Persero) Tbk | Laporan Tahunan 2018

Satu-satunya pabrik pengolah tambang iodium di Indonesia. Memproduksi bahan baku ferrous sulphate sebagai bahan utama pembuatan tablet besi untuk obat penambah darah, serta kapsul lunak

The only plant that processing iodine mine in Indonesia. Producing raw materials such as ferrous sulphate as the main material in producing iron supplements for blood booster, and soft capsules

Plant Watudakon, Jombang, Jawa TimurWatudakon plant, Jombang, east Java

Manufaktur untuk produk non Betalaktam, hormon Kontrasepsi, aKDr (alat Kontrasepsi Dalam rahim), dan produk herbal.

Manufacturing for Non-Betalactam products, Contraceptive Hormones, IUDs (Intra-Uterine Contraception), and Herbal products.

Plant Bandung, Jawa BaratBandung plant, West Java

Manufaktur produk farmasi dan herbal.

Manufacturing for pharma product and Herbal product.

Plant Banjaran, Jawa BaratBanjaran plant, West Java

It is the only plant in Indonesia that has been assigned by the Government to produce antiretroviral drugs (ARV).

Plant Jakarta, JakartaJakarta plant, Jakarta

Merupakan satu-satunya pabrik di Indonesia yang ditugaskan pemerintah untuk memproduksi arV (antiretroviral).

Khusus memproduksi minyak jarak, edible oils, dan kosmetika

Memproduksi non Betalaktam dengan sediaan tablet, krim dan kapsul

Spesifically producing castor oil, edible oils, and cosmetics

Producing Non Betalactam products, tablet, cream, and capsule

Plant Semarang, Jawa TengahSemarang plant, Central Java

Plant Medan, Sumatera utaraMedan plant, north Sumatera

13


pabrik Farmasi: Menghadirkan produk Bermutu dan BerkualitasPharmaceutical Plant: Presenting High Quality Product


Management Report

Company Profile





PabrikFarmasiPerseroantelahmendapatsertifikatCarapembuatan obat yang Baik (CpoB), Cara pembuatan obat Tradisional yang Baik (CpoTB), Cara pembuatan KosmetikayangBaik(CPKB),sertifikatISO9001:2015tentang Sistem Jaminan Mutu, dan ISo 14001:2015 tentang Sistem Manajemen Lingkungan

Pharmaceutical Plants of the Company have received certificates of Good Manufacturing Practices (CPOB), Good Manufacturing Practices of Traditional Medicine (CPOTB), and Good Manufacturing Methods for Cosmetics (CPKB), ISO 9001: 2015 certificates about Quality Assurance Systems, and ISO 14001: 2015 about Environmental Management Systems.

annual report 2018 | PT Kimia Farma (Persero) Tbk eNHANCING QuAlITy PRoVIDING THe BeST

“Kimia Farma memiliki pabrik Farmasi sebagai usaha utama perseroan. hasil produk dari pabrik Farmasi Kimia Farma didistribusikan ke seluruh

Indonesia dan luar negeri, sebagai bagian dari komitmen Kimia Farma untuk memajukan industri farmasi Indonesia.”

“Kimia Farma has Pharmaceutical Plants as the Company’s main business. Products from the Kimia Farma Pharmaceutical Plants are distributed throughout Indonesia

and overseas, as part of Kimia Farma’s commitment to advance the Indonesian pharmaceutical industry.”

Manufaktur alat kesehatan, antara lain tes HIV,tesSifilis,tesHepatitisC,tesMalaria,tes narkoba, dan tes Kehamilan.

Manufacturing for medical equipment, such as HIV test, Sifilis test, Hepatitis C test, Malaria test, Narcotics test, and Pregnancy test.

Plant Denpasar, BaliBandung plant, West Java

14


Digitalisasi Farmasi: Transformasi Menuju Industri Farmasi Masa DepanPharmacy Digitalization: Transformation towards The Future of Pharmaceutical IndustryDigitalisasi Farmasi: Transformasi Menuju Industri Farmasi Masa DepanPharmacy Digitalization: Transformation towards The Future of Pharmaceutical Industry

Kimia Farma telah mengembangkan teknologi nomor serial produk berupa Qr Code yang tertera pada kemasan produk. nomor serial ini berguna untuk melakukan perhitungan persediaan produk secara daring, atau melakukan pelacakan jika terdapat keluhan pelanggan atas produk hasil manufaktur Kimia Farma.

Kimia Farma has developed a product serial number technology in the form of a QR Code that printed on the product packaging. This serial number is useful for calculating product inventory online, or tracking the product if there is customer complaint about Kimia Farma’s manufactured products.

15


Digitalisasi Farmasi: Transformasi Menuju Industri Farmasi Masa DepanPharmacy Digitalization: Transformation towards The Future of Pharmaceutical Industry


Management Report

Company Profile





“Transformasi Digital telah dilakukan Kimia Farma untuk dapat mendukung strategi perluasan channel, pemasaran digital, branding, serta pengembangan organisasi.”

“Digital Transformation has been carried out by Kimia Farma to support Channel expansion strategy, digital marketing, branding, and organizational development.”

16


pencapaian Tahun 2018Achievement of 2018pencapaian Tahun 2018Achievement of 2018

Jumlah penyaluran program Kemitraanyang disalurkan kepada 184 Mitra Binaan yang tersebar di 7 wilayah di Indonesia.

Total Distribution of Partnership Program This was distributed to 184 Development Partners spread across 7 regions in Indonesia.

*) Salinan Keputusan Sekretaris Kementerian BUMN No. SK-16/S.MBU/2012 tanggal 6 Juni 2012 tentang Indikator/Parameter Penilaian dan Evaluasi atas Penerapan Tata Kelola Perusahaan yang Baik (Good Corporate Governance) pada BUMN**) Pelaksanaan KPKU sesuai intruksi Kementerian BUMN melalui surat No. S-198/D7.MBU/10/2017 tentang Pelaksanaan Assessment Implementasi KPKU BUMN Tahun 2017. Pada tahun 2018 tidak dilakukan evaluasi implementasi KPKU, sesuai surat edaran Forum Ekselen BUMN No. S08/D7.MBU/01/2019 tanggal 23 Januari 2019. Evaluasi tahun 2018 menggunakan hasil tahun 2017

PertumbuhanJumlahAsetTotal Assets Growth

dari rp6,10 triliun di tahun 2017 menjadi rp9,46 triliun di tahun 2018.From IDR 6.10 trillion in 2017 to IDR 9.46 trillion in 2018.

55,19%

PertumbuhanJumlahAsetTotal Fixed Assets Growth

dari rp6,10 triliun di tahun 2017 menjadi rp9,46 triliun di tahun 2018.From IDR 1.77 trillion in 2017 to IDR 2.69 trillion in 2018.

52,54%

PeningkatanEkuitasIncrease in Equity

dari rp2,57 triliun di tahun 2017 menjadi rp3,36 triliun di tahun 2018.From IDr 2.57 trillion in 2017 to IDr 3.36 trillion in 2018.

30,47%

KenaikanPendapatanBersihIncrease in Net Income

dari rp6,13 triliun di tahun 2017 menjadi rp7,45 triliun di tahun 2018.From IDr 6.13 trillion in 2017 to IDr 7.45 trillion in 2018.

21,65%

5,92miliar billion

Rp

hasil assessment* penerapan Tata Kelola perusahaan yang Baik, meningkat dari hasil assessment tahun 2017 dengan skor 84,52 berpredikat “Baik”.

Assessment results * of the implementation of Good Corporate Governance, increased from the results of 2017 assessment with a score of 84.52 predicated “Good”.

91,82 “SangatBaik”“Very Good”

17


pencapaian Tahun 2018Achievement of 2018


Management Report

Company Profile





Jumlah penyaluran program Bina Lingkunganyang disalurkan melalui 7 sektor yang dapat berimbas langsung terhadap

masyarakat, dan disalurkan melalui 13 wilayah di Indonesia.

*Copy of Decree of the Secretary of SEOs Ministry No. SK-16 / S.MBU / 2012 dated June 6, 2012 concerning Indicators / Parameters for Assesment and Evaluating the Implementation of Good Corporate Governance in SOE

*The implementation of KPKU is in accordance with the instructions of the SEOs Ministry through letter No. S-198/D7.MBU/10/2017 regarding the Implementation of 2017 SEO KPKU Assessment. In 2018, the evaluation of the implementation of the KPKU was not carried out, according to the circular letter of the SEO excellent forum no. S08 / D7.MBU / 01/2019 dated January 23, 2019. Evaluation in

2018 uses the results of 2017

Total Distribution of Community Development Program This was distributed through 7 sectors that can directly impact the

community, and distributed through 13 regions in Indonesia.

KenaikanLabaTahunBerjalanIncrease in Profit Current Year

dari rp331,71 miliar di tahun 2017 menjadi rp401,79 miliar di tahun 2018.

From IDR 331.71 billion in 2017 to IDR 401.79 billion in 2018.

21,13%

KenaikanLabayangDapatDiatribusikanKepadaPemilikEntitasInduk

Profit (Loss) Attributable to Owners of Parent Entity

dari rp6,10 triliun di tahun 2017 menjadi rp9,46 triliun di tahun 2018.

From IDR 326.79 billion in 2017 to IDR 415.90 billion in 2018.

27,27%

JumlahProdukHasilManufakturKimiaFarma

Kimia Farma Total Manufactured Products

item

meliputi etikal, obat bebas, generik, narkotika, lisensi dan bahan baku.

Including ethical, over-the-counter, generic, narcotics, licenses and raw materials.

495

PemenuhanTargetVolumeProduksiyangBerhasilDirealisasikandiTahun2018

Fulfillment of Successful Production Volume Targets that Realized in 2018

Total rata-rata manufaktur Kimia Farma di tahun 2018 mengalami pertumbuhan

produksi sebesar 19,52%.

The total average manufacturing of Kimia Farma in 2018 experienced a production

growth of 19.52%.

127,19%

3,43miliar billion

Rp

hasil evaluasi Kriteria penilaian Kinerja unggul (KpKu) tahun 2017**, meningkat dari hasil KpKu tahun 2017 dengan skor 477,25.

Results of evaluation of the Superior Performance Assessment Criteria (KPKU) in 2017 **, increased from the results of 2017 KPKU with a score of 477.25

490,75“GoodPerformance”“Good Performance”

18


Daftar IsiTable of Contents

Sanggahan dan Batasan Tanggung JawabDisclaimer and Limitation of Liability 3

Tentang Laporan Tahunan pt Kimia Farma (persero) Tbk Tahun 2018About PT Kimia Farma (Persero) Tbk Annual Report of 2018

4


5

Kesinambungan TemaThemes Continuity 6

penjelasan TemaTheme Explanation 7

Jejak LangkahMilestone 8

Sinergi Layanan Kesehatan dari hulu hingga ke hilirHealth Service Synergy from Upstream to Downstream

10

pabrik Farmasi: Menghadirkan produk Bermutu dan BerkualitasPharmaceutical Plant: Presenting High Quality Product

12

Digital Farmasi: Transformasi Menuju Industri Farmasi Masa DepanDigital Pharmacy: Transformation towards The Future of Pharmaceutical Industry

14

pencapaian Tahun 2018Achievement of 2018 16

Daftar IsiTable of Contents 18

Komposisi pemegang SahamShareholder Composition 102

Daftar entitas anak dan entitas asosiasi Serta Joint Venture (JV) dan Special purpose Vehicle (SpV)List of Subsidiaries and Associates Entities as well as Joint Ventures (JV) and Special Purpose Vehicle (SPV)

108

Struktur grup Kimia FarmaKimia Farma Group Structure 120

Kronologis penerbitan dan pencatatan SahamChronology of Share Issueance and Listing 122

Informasi Tentang penerbitan Dan pencatatan obligasi Serta efek LainnyaInformation of Bond Issueance and Listing and/or Other Securities

125

Lembaga dan profesi penunjangSupporting Institution and Professional 126

PenghargaandanSertifikasiAwards and Sertifications 128

Daftar alamat entitas anak dan Kantor Jaringan operasional, Serta Informasi Kantor Cabang dan Kantor perwakilanSubsidiaries and Operational Network Office Address List, and Branch Office and Representative Office Information

130

Informasi pada Situs Web perusahaanInformation on Company Website 132

Ikhtisar Keuanganperformance highlights

Laporan ManajemenManagement report

ProfilperusahaanCompany Profile

Informasi umum dan Identitas perusahaanGeneral Information and Company Identity 72

riwayat Singkat perusahaanBrief History of Company 74

Bidang usahaBusiness Line 76

Struktur organisasiOrganization Structure 79

Visi, Misi dan nilai-nilai Inti perusahaanVision, Mission, and Corporate Values 80

Makna Logo perusahaanDefinition Of Kimia Farma Logo 83

ProfilDewanKomisarisBoard of Commissioners Profile 84

ProfilDireksiBoard of Directors Profile 89

ProfilPejabatEksekutifExecutive Officer Profile 94

DemografiKaryawanDanPengembanganKompetensiEmployee Demographic and Competency Development

98

pergerakan Jumlah Karyawan dalam 5 (Lima) Tahun TerakhirMovement of Employees Number in Last (Five) Years

98

Ikhtisar Data Keuangan pentingSummary of Important Financial Data 22

Ikhtisar SahamShare Overview 26

Informasi Tentang penerbitan obligasi, Sukuk atau obligasi KonversiInformation on Issuance of Bonds, Conventional Bonds or Conversion Bonds

30

Informasi Sumber pendanaan lainnyaInformation on Other Funding Sources 30

peristiwa pentingFinancial Highlights 32

Laporan Dewan KomisarisBoard of Commissioners’s Report 46

Laporan DireksiDirector’s Report 58

pernyataan Dewan Komisaris dan Direksi Tentang Tanggung Jawab atas Laporan Tahunan 2018 pT Kimia Farma (persero) TbkResponsibility Statetement Of The Board Of Commissioners And Board Of Directors for 2018 Annual Report of PT Kimia Farma (Persero) Tbk

70

19


Tinjauan perekonomian Dan IndustriReview Of Economy And Industry


Management Report

Company Profile





Tata Kelola perusahaanCorporate governance

Laporan KeuanganFinancial report

Indeks Bapepam LK X.K.6 dan araCross Reference of Bapepam-LK Regulation No X.K.6 709

pemahaman Tentang Tata Kelola perusahaan yang Baik

Understanding About Good Corporate Governance248

perkembangan penerapan Tata Kelola perusahaan yang Baik di Lingkup Kimia Farma

Development Of The Implementation Of Good Corporate Governance In Kimia Farma

250

Struktur organ Tata Kelola perusahaan yang BaikGood Corporate Governance Organ Structure 307

Manajemen risikoRisk management 460

Sistem pengendalian InternalSistem Pengendalian Internal 471

Corporate Social responsibilityCorporate Social Responsibility 473

perkara pentingPerkara Penting 474

akses Informasi dan Data perusahaanAccess to Company Information And Data 474

Kode etikCode of Conducts 482

Tinjauan perekonomian Dan IndustriReview Of Economy And Industry 136

Inisiasi Strategis 2018Strategic Initiation Of 2018 140

Tinjauan operasi per Segmen usahaOperational Review Of Business Segments 142

Tinjauan KeuanganFinancial Review 171

prospek usahaBusiness Prospect 202

aspek pemasaranMarketing Aspect 205

Tinjauan Keuangan LainnyaOther Financial Reviews 206

Informasi Kelangsungan usahaBusiness Sustainability 216

peta Jalan usaha: rencana Jangka panjangBusiness Roadmap: Long-Term Plan 218

analisis dan pembahasan Manajemen

Management Discussion & analysis

Fungsi penunjang BisnisBusiness Support Functions Tanggung Jawab Sosial

perusahaanBusiness Support FunctionsTumbuh Bersama Karyawan: pengelolaan

Sumber Daya ManusiaGrowing With Employees: Management Of Human

Resources

222

Menjemput perubahan: pengembangan dan optimalisasi Teknologi Informasi

Pick Up The Change : Development And Optimization Information Technology

239

PengendalianGratifikasiGratification Control 489

Informasi pemberian Dana untuk Kegiatan politikInformation of Political Activities Funding 491

Kebijakan anti KorupsiAnti-Corruption Policy 491

Laporan harta Kekayaan penyelenggara negara (LhKpn)

Assets Report Of State Administator 492

Kebijakan pengadaan Barang dan JasaGoods and Services Procurement Policy 496

Whistleblowing SystemWhistleblowing System 497

Keberagaman Komposisi Dewan Komisaris dan Direksi

The Composition Diversity of Board of Commissioners and Directors

502

Transparansi praktik Bad governanceTransparency of Bad Governance Practices 506

Kepatuhan atas pedoman Tata Kelola perusahaan Terbuka: Kesesuaian terhadap

SeoJK no. 32/SeoJK.04/2015Compliance With The Governance Guidelines Of Public

Company: Regarding SEOJK No. 32/SEOJK.04/2015

508

Tanggung Jawab Sosial perusahaan dan pembangunan Berkelanjutan: Sebuah pendekatan

Corporate Social Responsibility And Sustainable Development: An Approach

534

Kebijakan penerapan Tanggung Jawab Sosial perusahaan di Lingkup Kimia Farma

Policy Of Corporate Social Responsibility Implementation In The Scope Of Kimia Farma

537

Tanggung Jawab Sosial perusahaan Bidang Lingkungan

Corporate Social Responsibility In The Field Of Environment

544

Tanggung Jawab Sosial perusahaan Bidang Ketenagakerjaan, Kesehatan dan Keselamatan

KerjaCorporate Social Responsibility In The Field Of Labor,

Health And Safety

552

Tanggung Jawab Sosial perusahaan Bidang pengembangan Sosial dan Kemasyarakatan

Corporate Social Responsibility In The Field Of Social And Community Development

559

Tanggung Jawab Sosial perusahaan Lingkup Tanggung Jawab Terhadap produk/Jasa Serta

Konsumen dan Mitra KerjaCorporate Social Responsibility In The Scope Of

Responsibility For The Product / Services And Consumer And Business Partners

579

Ikhtisar KeuanganPerformance Highlights

Transformasi digital yang diusung sebagai bagian dari perubahan mendasar dalam proses bisnis Kimia Farma. “Digital Farmasi”, demikian konsep yang diusung Kimia Farma,

Digital transformation which is carried out as part of a fundamental change in the Kimia Farma business process. “Digital Pharmacy”, according to the concept promoted by Kimia Farma,

22

Meningkatkan kualitas, Menghadirkan yang terbaik PT Kimia Farma (Persero) Tbk | Laporan Tahunan 2018

Ikhtisar Keuangan

Ikhtisar Data Keuangan PentingSummary of Important Financial Data

Laba (Rugi) dan Penghasilan Komprehensif Lain KonsolidasianConsolidated Profit (Loss) and Other Comprehensive Income

(Dalam Jutaan Rupiah)(In million rupiah) 2018 2017 2016 2015 2014

YoY 2017-2018

CAGR 2014-2018

(%) (%)

PenjualanSales 7.454.115 6.127.479 5.811.503 4.860.371 4.521.024 21,65% 13,32%

Beban Pokok PenjualanCost of goods sold (4.673.936) (3.925.600) (3.947.607) (3.323.619) (3.135.542) 19,06% 10,49%

Laba KotorGross profit 2.780.178 2.201.880 1.863.896 1.536.752 1.385.483 26,26% 19,02%

Laba UsahaOperating profit 765.017 535.661 442.824 391.047 370.887 42,82% 19,84%

Beban KeuanganFinance Expenses (187.291) (85.952) (59.798) (36.143) (26.869) 117,90% 62,49%

Laba Sebelum PajakProfit before tax 577.726 449.710 383.026 354.905 344.018 28,47% 13,84%

Manfaat (Beban) Pajak PenghasilanIncome Tax (Loss) Benefits

(175.934) (118.002) (111.428) (89.355) (86.182) 49,09% 19,53%

Laba Tahun BerjalanCurrent year profit 401.793 331.708 271.598 265.550 257.836 21,13% 11,73%

Pendapatan (Beban) Komprehensif LainnyaOther Comprehensive Income (Expenses)

373.909 (7.841) (24.705) (65.029) 6.055 4868,64% 180,33%

Laba KomprehensifComprehensive Profit 775.702 323.867 246.893 200.520 263.891 139,51% 30,94%

Laba yang Dapat Diatribusikan kepadaIncome Attributable to

Pemilik Entitas IndukOwners of the Parent Entity 415.896 326.786 267.414 261.426 255.931 27,27% 12,91%

Kepentingan Non PengendaliNon-controlling interests (14.103) 4.922 4.184 4.123 1.905 -386,53% N.A

Laba Komprehensif yang Dapat Diatribusikan kepadaComprehensive Income Attributable to

Pemilik Entitas IndukOwners of the Parent Entity 786.883 318.945 242.709 196.397 261.985 146,71% 31,65%

Kepentingan Non-PengendaliNon-controlling interests (11.181) 4.922 4.184 4.123 1.905 -327,17% N.A

Jumlah Saham Beredar (dalam juta lembar)Total outstanding shares (in million shares)

5.554 5.554 5.554 5.554 5.554 - -

Laba Bersih per Saham (dalam Rupiah penuh)Net Income per Share (in Rupiah)

74,88 58,84 48,15 47,07 46,08 27,26% 12,91%

23

Annual Report 2018 | PT Kimia Farma (Persero) Tbk Enhancing Quality Providing thE BEst



Management Report

Company Profile






Management Report

Company Profile





Laba Tahun BerjalanCurrent Year Profit

Jutaan RupiahMillions of Rupiah

PenjualanSales


4.521.0244.860.371

5.811.5036.127.479

7.454.115

20182017201620152014

CAGR 13,32% CAGR 11,73%

257.836265.550

271.598331.708

401.793

20182017201620152014

255.931261.426

267.414326.786

415.896

20182017201620152014

CAGR 12,91%


Laba yang Dapat Diatribusikan kepada Pemilik Entitas IndukProfit Attributable to Owners of the Parent Entity

46,0847,07

48,1558,84

74,88

20182017201620152014

CAGR 12,91%

Laba per Lembar DasarEarnings per Share


Posisi Keuangan KonsolidasianConsolidated Financial Position


YoY 2017-2018

CAGR 2014-2018

(%) (%)

Aset LancarCurrent assets 5.369.547 3.662.090 2.906.737 2.100.922 2.040.431 46,63% 27,37%

Aset Tidak LancarNon-Current Assets 4.090.881 2.434.059 1.705.825 1.333.957 1.154.233 68,07% 37,21%

Jumlah AsetTotal assets 9.460.427 6.096.149 4.612.562 3.434.879 3.194.664 55,19% 31,18%

24



Ikhtisar Keuangan

Posisi Keuangan KonsolidasianConsolidated Financial Position


YoY 2017-2018

CAGR 2014-2018

(%) (%)

Liabilitas Jangka PendekShort-term liabilities 3.774.304 2.369.507 1.696.209 1.092.624 854.812 59,29% 44,96%

Liabilitas Jangka PanjangLong-term Liabilities 2.329.663 1.154.121 644.946 285.696 436.888 101,86% 51,96%

Jumlah LiabilitasTotal Liability 6.103.968 3.523.628 2.341.155 1.378.320 1.291.700 73,23% 47,44%

Jumlah EkuitasTotal Equity 3.356.460 2.572.521 2.271.407 2.056.560 1.902.964 30,47% 15,24%

Investasi pada Entitas LainInvestment in Other Entities 165.000 165.000 165.000 165.654 165.706 0,00% -0,11%

Modal Kerja BersihNet Working Capital 1.595.243 1.292.583 1.210.528 1.008.298 1.185.619 23,42% 7,70%

LiabilitasLiabilities


AsetAssets


3.194.6643.434.879

4.612.5626.096.149

9.460.427

20182017201620152014

CAGR 31,18%

1.291.7001.378.320

2.341.1553.523.628

6.103.968

20182017201620152014

CAGR 47,44%

1.902.9642.056.560

2.271.4072.572.521

3.356.460

20182017201620152014

CAGR 15,24%

EkuitasEquity


25




Management Report

Company Profile






Management Report

Company Profile





Rasio-rasio KeuanganFinancial Ratios

SatuanSatuan 2018 2017 2016 2015 2014

YoY 2017-2018

CAGR 2014-2018

(%) (%)

Imbal Hasil InvestasiReturn on Investment % 8,09 8,79 9,6 11,38 11,61 -7,96% -8,64%

Imbal Hasil EkuitasReturn on Equity % 11,61 13,7 12,36 13,2 14,59 -15,26% -5,55%

Imbal Hasil AsetReturn on Asset % 3,45 5,36 5,8 7,61 8,07 -35,63% -19,14%

Margin Laba KotorGross Profit Margin % 37,30 35,93 32,07 31,62 30,65 3,81% 5,03%

Margin Laba BersihNet Profit Margin % 5,39 5,41 4,67 5,46 5,7 -0,37% -1,39%

Rasio Perputaran AsetAsset Turnover Ratio % 115,61 127,81 148,09 146,63 146,52 -9,55% -5,75%

Rasio LancarCurrent Ratio

x (kali)(times) 1,42 1,55 1,71 1,92 2,39 -8,39% -12,20%

Rasio CepatQuick ratio

x (kali)(times) 0,94 1,04 1,14 1,24 1,58 -9,62% -12,18%

Rasio Utang Jangka PanjangLong Term Debt Ratio % 38,17 32,75 27,55 20,73 33,82 16,55% 3,07%

Rasio Liabilitas terhadap Jumlah AsetLiability ratio to total assets

% 64,52 57,8 50,76 40,13 40,43 11,63% 12,40%

Rasio Liabilitas terhadap Jumlah EkuitasLiability Ratio to Total Equity

% 181,86 136,97 103,07 67,02 67,88 32,77% 27,94%

Margin Laba KotorGross Profit Margin


30,6531,62

32,0735,93

37,30

20182017201620152014

CAGR 5,03%

Rasio Liabilitas terhadapJumlah EkuitasLiability Ratio to Total Equity


67,8867,02

103,07

136,97

181,86

20182017201620152014

CAGR 27,94%

26


Ikhtisar SahamShare Overview

Ikhtisar Keuangan


Informasi Pergerakan Saham

Kode Saham: KAEF | Bursa Perdagangan Saham: Bursa Efek IndonesiaStock Code: KAEF | Stock Exchange Trading: Indonesia Stock Exchange


PeriodePeriod

Harga Saham PembukaanOpening Stock Price

Harga Saham TertinggiHigest Stock Price



Kapitalisasi PasarMarket

Capitalization

TransaksiTransaction

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalDate

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalDate

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalTanggal

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalDate

(Rp juta)(Rp million)

Vol (ribu/lmbr)Vol (thousand/

share)

Val (Rp juta)Val (Rp million)

Frek(X)Frek(X)

2018

Triwulan IQuarter I 2.700 02/01/18 2.730 02/01/18 2.030 20/03/18 2.190 29/03/18 12.163.000 51.932 128.398 26.797

Triwulan IIQuarter II 2.190 02/04/18 2.880 31/05/18 1.990 24/05/18 2.360 29/06/18 13.107.000 40.208 97.572 15.491

Triwulan IIIQuarter II 2.360 02/07/18 2.730 25/09/18 2.010 05/09/18 2.550 28/09/18 14.163.000 20.738 50.255 8.740

Triwulan IVQuarter IV 2.470 01/10/18 3.000 13/12/18 2.300 05/10/18 2.600 12/28/218 14.440.000 37.662 97.073 7.913

2017



Quarter IIITriwulan II 2.890 03/07/17 3.400 25/08/17 2.690 28/09/17 2.740 29/09/17 15.218.000 108.906 341.689 31.875


Information on Stock Movements

27




Management Report

Company Profile






Management Report

Company Profile





Informasi Pergerakan Saham



PeriodePeriod





Kapitalisasi PasarMarket

Capitalization

TransaksiTransaction

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalDate

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalDate

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalTanggal

Harga(Rp/lembar

saham)Price

(Rp/share)

TanggalDate

(Rp juta)(Rp million)

Vol (ribu/lmbr)Vol (thousand/

share)

Val (Rp juta)Val (Rp million)

Frek(X)Frek(X)

2018



Triwulan IIIQuarter II 2.360 02/07/18 2.730 25/09/18 2.010 05/09/18 2.550 28/09/18 14.163.000 20.738 50.255 8.740


2017



Quarter IIITriwulan II 2.890 03/07/17 3.400 25/08/17 2.690 28/09/17 2.740 29/09/17 15.218.000 108.906 341.689 31.875


28



Ikhtisar Keuangan

Informasi Saham KAEF 2014 - 2018KAEF Stock Information 2014 - 2018

2018 2017 2016 2015 2014

Harga Pembukaan (Rp/per lembar saham)Opening Price (Rp / per share)

2.700 2.750 870 1.470 590

Harga Tertinggi (Rp/per lembar saham)Highest Price (Rp / per share) 3.000 2.960 2.860 1.475 1.640

Harga Terendah (Rp/per lembar saham)Lowest Price (Rp / per share) 1.990 1.795 1.155 590 580

Harga Penutupan (Rp/per lembar saham)Closing Price (Rp / per share) 2.600 2.700 2.750 870 1.465

Nilai Buku Per Saham (Rp)Book Value Per Share (Rp) 501 463 409 335 326

Price to Book Value (%)Price to Book Value (%) 6,36* 4,73 5,99 3,59 3,43

Price to Earning Ratio (%)Price to Earning Ratio (%) 59* 37,22 50,88 26,89 26,51

Jumlah Saham Beredar (juta lembar saham)Total outstanding shares (million shares)

5.554 5.554 5.554 5.554 5.554

*Laporan keuangan September 2018 *financial report September 2018

Harga Penutupan dan Volume Perdagangan KAEF 2017 - 2018Chart of KAEF Closing Price and Trading Volume 2017 - 2018

Volume PerdaganganTrading Volume

Harga PenutupanClosing Price

JAN 17 FEB 17 MAR 17 APR 17 MAY 17 JUN 17 JUL 17 AUG 17 SEP 17 OCT 17 NOV 17 DEC 17 JAN 18 FEB 18 MAR 18 APR 18 MAY 18 JUN 18 JUL 18 AUG 18 SEP 18 OCT 18 NOV 18 DEC 18

29




Management Report

Company Profile






Management Report

Company Profile





Aksi Korporasi Saham

Di tahun 2018 Perseroan tidak melakukan aksi pemecahan saham (stock split), penggabungan saham (reverse stock), saham bonus, dan perubahan nilai nominal saham.

Dividen saham yang dibagikan Perseroan pada tahun 2017 dan 2018 adalah sebagai berikut:

Dividen SahamStock Dividend

Tahun Pembagian 2018(untuk Dividen Saham

Tahun Buku 2017)Distribution in 2018(for FY 2017 Stock

Dividend)

Tahun Pembagian 2017(untuk Dividen Saham

Tahun Buku 2016)Distribution in 2017(for FY 2016 Stock

Dividend)

Peningkatan (Penurunan)

Increase (Decrease)

Laba Bersih Tahun Berjalan (Rp)Current Year Net Profit (Rp) 401.792.808.948 331.707.917.461 21,13%

Cadangan Umum (Rp)General Reserves (Rp) 228.702.609.091 213.929.072.891 6,91%

Dividen Kas yang Dibagikan (Rp)Cash Dividend Paid (Rp) 98.083.640.000 53.485.020.000 83,39%

Dividen per Lembar Saham (%/lembar saham)Dividends per Share (% / share)

17,66 9,63 83,39%

Rasio Pembayaran Dividen (%)Dividend Payment Ratio (%) 30,00% 20,00% 50,00%

Tanggal PengumumanDeclaration Date

23 April 201823 April 2018

25 April 201725 April 2017

Tanggal PembayaranPayment date

23 Mei 201823 May 2018

24 Mei 201724 May 2017

Di sepanjang tahun 2018, perdagangan saham Perseroan dengan kode saham KAEF tidak mengalami penghentian sementara perdagangan saham (suspension). Perseroan juga tidak melakukan penghapusan pencatatan saham (delisting) dalam tahun buku.

Informasi Penghentian Sementara dan/atau Sanksi Perdagangan Saham KAEF serta Penghapusan Pencatatan Saham

Hingga 31 Desember 2018, saham Perseroan tidak pernah menerima sanksi yang berpengaruh pada aktivitas perdagangan saham di Bursa Efek tempat mencatatkan dan memperdagangkan saham baik berupa penghentian perdagangan saham sementara (suspension). Perseroan juga tidak melakukan penghapusan pencatatan saham (delisting).

Stock Corporate Action

In 2018 the Company did not take stock split, reverse stock, bonus shares, and changes in share nominal value.

The stock dividends distributed by the Company in 2017 and 2018 are as follows:

Throughout 2018, the trading of the Company’s shares with the stock code of KAEF did not experience a temporary suspension of stock trading. Beside that, the Company also did not conduct any delisting in the Fiscal Year.

Information on Suspention and/or KAEF Stock Trading Sanctions and Delisting

As of December 31, 2018, the Company’s shares had never received sanctions that have an effect on stock trading activities at the Stock Exchange where the shares are listed and traded in the form of suspension of temporary stock trading. Also, the company did not commit any delisting.

30


Informasi Tentang Penerbitan Obligasi, Sukuk atau Obligasi KonversiInformation on Issuance of Bonds, Conventional Bonds or Conversion Bonds

Ikhtisar Keuangan


Informasi Sumber Pendanaan lainnyaInformation on Other Funding Sources

Hingga akhir tahun 2018, Perseroan tidak menerbitkan obligasi, sukuk, obligasi konversi, maupun efek lainnya. Dengan demikian, tidak terdapat informasi terkait jumlah obligasi/sukuk/obligasi konversi yang beredar (outstanding), tingkat bunga/imbalan, tanggal jatuh tempo, dan peringkat obligasi/sukuk.

Until the end of 2018, the Company did not issue bonds, conventional bond, convertible bonds, or other securities. Therefore, there is no information on the number of outstanding bonds/conventional bond/convertible bonds, interest/reward rates, maturity dates, and conventional bond/bond ratings

Berikut disampaikan penerbitan Surat Utang Jangka Menengah yang dikeluarkan Perseroan hingga akhir tahun 2018.

Ikhtisar Penerbitan Surat Utang Jangka Menengah (Medium Term Notes)Overview of the Issuance of Medium Term Notes

NamaName

Pokok Pinjaman (Rp Miliar)Principal Loan (Rp Billion)

Tingkat Suku Bunga

Interest Rate

Jangka WaktuTime

Period

Jangka WaktuTime Period

Jatuh TempoDue Date

PeringkatRating

StatusStatus

MTN (2016) 300 8,25% p.a (tetap/fix)

18 bulan18 Months

25 September 2016 September 25, 2016

25 Februari 2018February 25, 2018

idAA- (stable outlook) dari PefindoidAA- (stable outlook) from Pefindo

Lunas (per 20 Februari 2018Paid off (as of 20 February 2018)

MTN Tahap I (2017) 400 8,10% p.a (tetap/fix)3 tahun3 years

15 September 2017 September 15, 2017

15 September 2020September 15, 2020


AktifActive

MTN Tahap II (2018) 600

7,75% p.a (tetap/fix)

3 tahun3 years

15 Maret 2018March 15, 2018

15 Maret 2021March 15, 2021


AktifActive

The following is the issuance of Medium Term Notes issued by the Company until the end of 2018.

31




Management Report

Company Profile






Management Report

Company Profile





32


Peristiwa PentingFinancial Highlights

Ikhtisar Keuangan


Denpasar, Bali / 24 Januari 2018Denpasar, Bali / January 24, 2018

Karangasem, Bali / 27 Januari 2018Karangasem, Bali / January 27, 2018

Peresmian Fasilitas Produksi Rapid Test PT Kimia Farma (Persero) Tbk di Denpasar, Bali oleh Menteri Kesehatan Republik Indonesia, Nila F. Moeloek dan Direktur Utama PT Kimia Farma (Persero) Tbk, Honesti Basyir yang didampingi oleh Pejabat Tinggi Kementerian Kesehatan Republik Indonesia serta Komisaris Utama PT Kimia Farma (Persero) Tbk.

Program Corporate Social Responsibility (CSR) PT Kimia Farma (Persero) Tbk untuk para korban erupsi Gunung Agung, Kabupaten Karangasem, Bali. Program CSR yang bekerja sama dengan Ikatan Istri Keluarga Kimia Farma (IIKKF) dan Perhimpunan Bulan Sabit Merah Indonesia Provinsi Bali ini menyalurkan bantuan obat-obatan dan logistik.

Official announcement of PT Kimia Farma (Persero) Tbk Rapid Test Production Facility in Denpasar, Bali by the Minister of Health of the Republic of Indonesia, Nila F. Moeloek and President Director of PT Kimia Farma (Persero) Tbk, Honesti Basyir who was accompanied by the Indonesian Ministry of Health High Official and President Commissioner of PT Kimia Farma (Persero) Tbk.

PT Kimia Farma (Persero) Tbk Corporate Social Responsibility (CSR) Program for Gunung Agung eruption victims, Karangasem Regency, Bali. The CSR program collaboration with the Ikatan Istri Keluarga Kimia Farma (IIKKF) and Indonesian Red Crescent Society of Bali Province distributed medical aid and logistics.

Jakarta / 5 Maret 2018Jakarta / March 5, 2018

Signing Ceremony Shareholder Agremeent Kimia Farma Dawaa antara PT Kimia Farma (Persero) Tbk dan Marei Bin Mahfouz Group, perusahaan di Arab Saudi yang bergerak di bidang kesehatan. Melalui aksi korporasi ini, PT Kimia Farma (Persero) Tbk menjadi pemegang saham mayoritas Dawaa Medical Limited Company, anak perusahaan Marei Bin Mahfouz Group, yakni dengan kepemilikan saham sebesar 60%.

Kimia Farma Dawaa Signing Ceremony Shareholder Agremeent between PT Kimia Farma (Persero) Tbk and Marei Bin Mahfouz Group, a company in Saudi Arabia that is engaged in the health sector. Through this corporate action, PT Kimia Farma (Persero) Tbk became the majority shareholder of Dawaa Medical Limited Company, a subsidiary of Marei Bin Mahfouz Group, with 60% share ownership.

33




Management Report

Company Profile






Management Report

Company Profile







Bandung, Jawa Barat / 24 Maret 2018Bandung, West Java / March 24, 2018

Penandatanganan Perjanjian Penerbitan dan Penunjukkan Agen Pemantau MTN (Medium Terms Notes) PT Kimia Farma (Persero) Tbk Tahap II Tahun 2018 senilai Rp 600 miliar untuk membiayai ekspansi bisnis (Capital Expenditure dan Operating Expenditure). Pihak arranger yang terlibat adalah PT BNI Sekuritas, PT Mandiri Sekuritas, PT Indo Premier Sekuritas, dan PT BNI (Persero) Tbk sebagai agen pemantau.

Penandatanganan Perjanjian Kerja Sama Pengelolaan Rumah Sakit dan Pelayanan Kesehatan antara Pertamedika IHC (Indonesia Healthcare Cooperation) dengan PT Kimia Farma (Persero) Tbk, PT Kimia Farma Apotek dan PT Kimia Farma Trading & Distribution. Penandatanganan disaksikan oleh Menteri BUMN Republik Indonesia, Rini M. Soemarno dan Menteri Kesehatan Republik Indonesia, Nila F. Moeloek.

Marcks’ Trade Gathering diselenggarakan di Kota Bandung, Jawa Barat sebagai wahana untuk memperkuat relationship dengan customers Marcks’, salah satu brand kosmetik PT Kimia Farma (Persero) Tbk sekaligus memperkenalkan varian produk Marcks’ Teens Compact Powder.

Signing of the Issuance and Monitoring Agent MTN (Medium Term Notes) Designation Agreement for PT Kimia Farma (Persero) Tbk Phase II Year 2018 worth IDR 600 billion to finance business expansion (Capital Expenditure and Operating Expenditure). The arranger involved were PT BNI Securities, PT Mandiri Sekuritas, PT Indo Premier Securities, and PT BNI (Persero) Tbk as monitoring agents.

The signing of the Cooperation Agreement on Hospital Management and Health Services between Pertamedika IHC (Indonesia Healthcare Cooperation) and PT Kimia Farma (Persero) Tbk, PT Kimia Farma Apotek and PT Kimia Farma Trading & Distribution. The signing was witnessed by SOEs Minister of Republic of Indonesia, Rini M. Soemarno and the Minister of Health of the Republic of Indonesia, Nila F. Moeloek.

The Marcks’ Trade Gathering was held in Bandung City, West Java as a tool to strengthen relationship with Marcks’ customers, one of the cosmetics brands of PT Kimia Farma (Persero) Tbk while introducing the Marcks’ Teens Compact Powder product variant.

34



Ikhtisar Keuangan

Bandung, Jawa Barat / 25 Maret 2018Bandung, West Java / March 25, 2018

Jakarta / 2 April 2018Jakarta / April 2, 2018

Kompetisi maraton Fituno 10K Run Challenge untuk pertama kali diselenggarakan di Kota Bandung, Jawa Barat yang diikuti oleh lebih dari 3.000 pelari. Ajang ini sekaligus meningkatkan brand awareness suplemen herbal untuk daya tahan tubuh, Fituno, yang diproduksi oleh PT Kimia Farma (Persero) Tbk.

Peresmian GO-LIVE SEVEN SOLUTION sebagai bagian dari implementasi program digitalisasi PT Kimia Farma (Persero) Tbk.

The Fituno 10K Run Challenge marathon competition was held for the first time Bandung, West Java, and more than 3,000 runners were participated. This event also increases brand awareness of herbal supplements for body endurance, Fituno, which is produced by PT Kimia Farma (Persero) Tbk.

The official announcement of GO-LIVE SEVEN SOLUTION as part of the implementation of the PT Kimia Farma (Persero) Tbk digitalization program.


Penandatanganan Perjanjian Kredit Bilateral antara PT Bank Rakyat Indonesia (Persero) Tbk dan PT Bank BRISyariah dengan PT Kimia Farma (Persero) Tbk.

Signing of the Bilateral Credit Agreement between PT Bank Rakyat Indonesia (Persero) Tbk and PT Bank BRI Syariah with PT Kimia Farma (Persero) Tbk.

35




Management Report

Company Profile






Management Report

Company Profile






Bogor, Jawa Barat / 10 April 2018Bogor, West Java/April 10, 2018


Penandatanganan Perjanjian Kerja Sama Sinergi BUMN antara PT Garuda Indonesia (Persero) Tbk dengan PT Kimia Farma (Persero) Tbk tentang Sinergi dalam Penyediaan dan Pemanfaatan Layanan Jasa Transportasi Udara dan Layanan Kesehatan. Penandatanganan disaksikan oleh Menteri Perhubungan Republik Indonesia, Budi Karya Sumadi dan Menteri Pariwisata Republik Indonesia, Arief Yahya.

Penandatanganan Kerja Sama antara PT Bogor Life Science and Technology dengan PT Kimia Farma (Persero) Tbk terkait produksi dan pemasaran produk tepung biskuit Clarias sup krim Laktiva yang merupakan hasil inovasi Institut Pertanian Bogor. Penandatanganan disaksikan oleh Menteri Riset, Teknologi dan Pendidikan Tinggi Republik Indonesia, Mohamad Nasir.

Penandatanganan Nota Kesepahaman antara Yayasan Tunas Muda IKKT (Ikatan Kesejahteraan Keluarga Tentara Nasional Indonesia) dan PT Kimia Farma (Persero) Tbk. Penandatanganan dilakukan oleh Panglima Tentara Nasional Indonesia, Marsekal TNI Hadi Tjahjanto; Pembina Yayasan Tunas Muda IKKT, Ny. Nani Hadi Tjahjanto; dan Direktur Utama PT Kimia Farma (Persero) Tbk, Honesti Basyir serta disaksikan oleh Menteri BUMN Republik Indonesia, Rini M. Soemarno.

The signing of the SOE Synergy Cooperation Agreement between PT Garuda Indonesia (Persero) Tbk and PT Kimia Farma (Persero) Tbk concerning Synergy in the Provision and Use of Air Transportation Services and Health Services. The signing was witnessed by the Minister of Transportation of the Republic of Indonesia, Budi Karya Sumadi and the Minister of Tourism of the Republic of Indonesia, Arief Yahya.

The Signing of Cooperation between PT Bogor Life Science and Technology with PT Kimia Farma (Persero) Tbk regarded to the production and marketing of Clarias Lactiva cream soup biscuit flour products which is the result of innovation from the Bogor Agricultural Institute. The signing was witnessed by the Minister of Research, Technology and Higher Education of Republic of Indonesia, Mohamad Nasir.

Signing of the Memorandum of Understanding between the Tunas Muda IKKT Foundation (Ikatan Kesejahteraan Keluarga Tentara Nasional Indonesia) and PT Kimia Farma (Persero) Tbk. The signing was carried out by the Commander of the Indonesian Armed Forces, Marshal TNI Hadi Tjahjanto; The founder of the Tunas Muda IKKT Foundation, Ny. Nani Hadi Tjahjanto; and President Director of PT Kimia Farma (Persero) Tbk, Honesti Basyir and witnessed by the Minister of SOE of the Republic of Indonesia, Rini M. Soemarno.

36



Ikhtisar Keuangan


Rapat Umum Pemegang Saham Tahunan PT Kimia Farma (Persero) Tbk Tahun Buku 2017. Di tengah ekspansi bisnis, PT Kimia Farma (Persero) Tbk bagikan dividen sebesar Rp 98 miliar atau 30% dari laba bersih Perseroan tahun 2017, yakni sebesar Rp 331,7 miliar.

Annual General Meeting of Shareholders of PT Kimia Farma (Persero) Tbk FY2017. In the middle of business expansion, PT Kimia Farma (Persero) Tbk shares dividends of Rp 98 billion or 30% of the Company’s net income in 2017, which is Rp 331.7 billion.


Penandatanganan Perjanjian Kerja Sama antara PT Kimia Farma (Persero) Tbk dan PT Rumah Sakit PELNI terkait penyediaan dan pemanfaatan layanan jasa kesehatan. Penadatanganan disaksikan oleh Menteri BUMN Republik Indonesia, Rini M. Soemarno. Sinergi antara PT Kimia Farma (Persero) Tbk dan PT Rumah Sakit PELNI tersebut untuk memanfaatkan potensi pengembangan bisnis yang melingkupi pengembangan bisnis obat-obatan, alat kesehatan dan penunjang medis rumah sakit dan klinik; ekspansi bisnis perumahsakitan termasuk akuisisi rumah sakit; dan pengembangan rumah sakit.

Signing of the Cooperation Agreement between PT Kimia Farma (Persero) Tbk and PT Rumah Sakit PELNI regarding the provision and utilization of health services. The signing was witnessed by the Minister of SOE of the Republic of Indonesia, Rini M. Soemarno. The synergy between PT Kimia Farma (Persero) Tbk and PT umah Sakit PELNI is to utilize the potential of business development which covers the development of medicines, medical devices and medical support for hospitals and clinics business; hospital business expansion including the acquisition of hospitals; and hospital development.

Bandung, Jawa Barat / 6 Mei 2018Bandung, West Java/May 6, 2018

Bertepatan dengan peringatan World Lupus Day 2018, PT Kimia Farma (Persero) Tbk bersinergi dengan Fakultas Kedokteran Universitas Padjadjaran, Sekolah Farmasi Institut Teknologi Bandung, dan Lembaga Swadaya Masyarakat nirlaba peduli Lupus Syamsi Dhuha Foundation meluncurkan obat herbal alternatif bagi Orang dengan Lupus (Odapus) yang bernama Lesikaf. Peluncuran Lesikaf dihadiri oleh Kepala Badan POM Republik Indonesia, Penny K. Lukito.

Coinciding with the commemoration of World Lupus Day 2018, PT Kimia Farma (Persero) Tbk synergized with the Faculty of Medicine, Padjadjaran University, School of Pharmacy Institut Teknologi Bandung, and non-profit public Organizations Peduli Lupus Syamsi Dhuha Foundation launched alternative herbal medicines for people with Lupus (Odapus) named Lesikaf. The launch of Lesikaf was attended by the Head of Drug and Food Control Agency of the Republic of Indonesia, Penny K. Lukito.

37




Management Report

Company Profile






Management Report

Company Profile





Jakarta / 17 Mei 2018Jakarta / May 17, 2018

Jakarta / 18 Mei 2018Jakarta / May 18, 2018

Bandung, Jawa Barat / 28 Mei 2018 Bandung, Jawa Barat /May 28, 2018

Penandatanganan Kredit Modal Kerja antara PT Bank Maybank Indonesia Tbk dan PT Kimia Farma (Persero) Tbk.

Penandatanganan Kredit Modal Kerja antara Indonesia Eximbank dan PT Kimia Farma (Persero) Tbk.

PT Kimia Farma (Persero) Tbk menyelenggarakan program Safari Panti Ramadhan dengan memberikan bantuan untuk 1.000 anak yatim piatu dan dhuafa di panti asuhan dan panti jompo.

Signing of Working Capital Credit between PT Bank Maybank Indonesia Tbk and PT Kimia Farma (Persero) Tbk.

Signing of Working Capital Credit between Indonesia Eximbank and PT Kimia Farma (Persero) Tbk

PT Kimia Farma (Persero) Tbk organized a Safari Panti Ramadhan program by providing aid for 1,000 orphans and poor people in or phanages and nursing homes.

38



Ikhtisar Keuangan

Jakarta / 5 Juli 2018Jakarta / July 5, 2018

PT Kimia Farma (Persero) Tbk menggelar program Mudik Bareng BUMN Bersama Kimia Farma dengan menyediakan 16 armada bus yang ditujukan untuk para karyawan dan pelanggan Kimia Farma serta masyarakat umum.

Sosialisasi Gratifikasi Kimia Farma Group oleh Komisi Pemberantasan Korupsi Republik Indonesia.

PT Kimia Farma (Persero) Tbk held a Mudik bareng BUMN program with Kimia Farma by providing 16 bus fleets intended for Kimia Farma employees and customers as well as the public community.

Gratification Socialization of Kimia Farma Group by the Corruption Eradication Commission of the Republic of Indonesia.

Yogyakarta / 20 Juli 2018Yogyakarta / July 20, 2018

Penandatanganan Nota Kesepahaman antara Universitas Gadjah Mada; Direktorat Industri Kimia, Tekstil, dan Aneka Kementerian Perindustrian Republik Indonesia dan PT Kimia Farma (Persero) Tbk.

Signing of Memorandum of Understanding between Gadjah Mada University; General Directorate of Chemical, Textile and Multifarious Industries of the Ministry of Industry of the Republic of Indonesia and PT Kimia Farma (Persero) Tbk.

Jakarta / 8 Juni 2018Jakarta / June 8, 2018

39




Management Report

Company Profile






Management Report

Company Profile





Bandung, Jawa Barat / 9 Agustus 2018Bandung, West Java/August 9, 2018

Jakarta / 14 Agustus 2018Jakarta / August 14, 2018

Penandatanganan Akad Pembiayaan Musyarakah antara PT Bank BNI Syariah dengan PT Kimia Farma (Persero) Tbk.

Sebagai wujud pengoptimalan fasilitas kesehatan, PT Kimia Farma (Persero) Tbk membuka sembilan Laboratorium Klinik secara serentak di sembilan kota. Salah satu Laboratorium Klinik yang diresmikan adalah Laboratorium Klinik Kimia Farma Flagship Diponegoro Bandung. Adapun delapan Laboratorium Klinik lain yang diresmikan berlokasi di Yogyakarta, Singaparna, Serang, Aceh, Pekanbaru, Cilacap, Mamuju, dan Ternate.

Penandatanganan Kredit Modal Kerja antara PT Kimia Farma (Persero) Tbk dan PT Bank Central Asia Tbk.

Signing of Musyarakah Financing Agreement between PT Bank BNI Syariah and PT Kimia Farma (Persero) Tbk.

As an act of optimizing health facilities, PT Kimia Farma (Persero) Tbk opened nine Clinical Laboratories together in nine cities. One of the Clinical Laboratories that officially announced was the Kimia Farma Flagship Clinical Laboratory Diponegoro Bandung. The eight other Clinical Laboratories officially announced are located in Yogyakarta, Singaparna, Serang, Aceh, Pekanbaru, Cilacap, Mamuju, and Ternate.

Signing of Working Capital Credit between PT Kimia Farma (Persero) Tbk and PT Bank Central Asia Tbk.

Jakarta / 31 Juli 2018Jakarta / July 31, 2018

40



Ikhtisar Keuangan

Bandar Lampung, Lampung / 17 Agustus 2018Bandar Lampung, Lampung / August 17, 2018

Penandatanganan Nota Kesepahaman Penyediaan dan Pemanfaatan Layanan Jasa Kesehatan & Perbankan dan Perjanjian Kerja Sama tentang Penyediaan dan Pemanfaatan Layanan Jasa Perbankan antara PT Bank Negara Indonesia (Persero) Tbk dan PT Kimia Farma (Persero) Tbk.

PT Kimia Farma (Persero) Tbk berpartisipasi dalam program BUMN Hadir untuk Negeri di Lampung pada peringatan Hari Ulang Tahun ke-73 Republik Indonesia.

Signing of the Memorandum of Understanding on the Provision and Use of Health & Banking Services and Cooperation Agreement on the Provision and Use of Banking Services between PT Bank Negara Indonesia (Persero) Tbk and PT Kimia Farma (Persero) Tbk.

PT Kimia Farma (Persero) Tbk participated in “BUMN Hadir untuk Negeri” program in Lampung on the commemoration of the 73rd Anniversary of the Republic of Indonesia.


Penandatanganan Nota Kesepahaman antara PT Kimia Farma (Persero) Tbk dan PT Biofarma (Persero).

Signing of Memorandum of Understanding betweenPT Kimia Farma (Persero) Tbk and PT Biofarma (Persero).


41




Management Report

Company Profile






Management Report

Company Profile





Lombok, Nusa Tenggara Barat / 20 September 2018West Nusa Tenggara/September 20, 2018

Jakarta / 17 Oktober 2018Jakarta / October 17, 2018

Untuk memperingati Hari Ulang Tahun ke-47, PT Kimia Farma (Persero) Tbk mengadakan program Kimia Farma Mengajar : Pengenalan Pola Hidup Bersih dan Sehat secara serentak di 47 kabupaten / kota. Pembukaan acara diselenggarakan di SD Negeri Kebon Kelapa 02, Gambir, Jakarta Pusat.

PT Kimia Farma (Persero) Tbk melalui program Kimia Farma Peduli Lombok menyalurkan bantuan untuk para korban gempa bumi di Lombok, Nusa Tenggara Barat. Bantuan yang disampaikan berupa bantuan obat untuk mengatasi diare bernama DiaResQ, pemeriksaan kesehatan dan sosialisasi pola hidup bersih dan sehat.

Peresmian pembukaan Hotel Holiday Inn Express Jakarta Matraman sebagai bagian dari optimalisasi aset PT Kimia Farma (Persero) Tbk dengan tetap mempertahankan inti bisnis Perseroan.

In order to commemorate the 47th Anniversary, PT Kimia Farma (Persero) Tbk held Kimia Farma Teaching Program: Introduction to the Clean and Healthy Lifestyle together in 47 districts/cities. The opening ceremony was held at SD Negeri Kebon Kelapa 02, Gambir, Central Jakarta.

PT Kimia Farma (Persero) Tbk through Kimia Farma Peduli Lombok Program distributed aids to earthquake victims in Lombok, West Nusa Tenggara. The aids that delivered were medicine to overcome diarrhea named DiaResQ, health checks and socialization of clean and healthy lifestyle.

The inauguration of the opening of the Holiday Inn Express Jakarta Matraman Hotel as part of optimizing the assets of PT Kimia Farma (Persero) Tbk while maintaining the Company’s core business.


42



Ikhtisar Keuangan

Gunungkidul, Yogyakarta / 15 November 2018Gunungkidul, Yogyakarta / November 15, 2018

Penandatanganan Fasilitas Kredit Modal Kerja antara PT Bank DKI Unit Usaha Syariah dan PT Kimia Farma (Persero) Tbk di Jakarta.

Sebagai wujud kepedulian dalam meningkatkan kualitas kesehatan masyarakat, PT Kimia Farma (Persero) Tbk dan Ikatan Istri Keluarga Kimia Farma (IIKKF) memberikan bantuan sarana air bersih di Desa Girisuko, Gunungkidul, Yogyakarta serta memberikan bantuan penampungan air dan pelatihan Keterampilan Kecakapan Hidup di Sekolah Luar Biasa (SLB) Purwoharjo, Gunungkidul, Yogayakarta.

Signing of the Working Capital Credit Facility between PT Bank DKI Syariah Business Unit and PT Kimia Farma (Persero) Tbk in Jakarta.

As a concern in improving the quality of public health, PT Kimia Farma (Persero) Tbk and the Ikatan Istri Keluarga Kimia Farma (IIKKF) provided clean water in Girisuko Village, Gunungkidul, Yogyakarta and provided water storage and Life Skills training in Sekolah Luar Biasa (SLB) Purwoharjo, Gunungkidul, Yogayakarta.

Jakarta / 19 Oktober 2018Jakarta / October 19, 2018

43




Management Report

Company Profile






Management Report

Company Profile





PT Kimia Farma (Persero) Tbk mendukung pengembangan kemandirian ekonomi di kalangan pondok pesantren melalui program Corporate Social Responsibility (CSR) Pemberdayaan Santri dengan membangun Kebun Gizi Hidroponik di Pondok Pesantren Hidayatullah, Depok, Jawa Barat.

PT Kimia Farma (Persero) Tbk supports the development of economic independence among boarding schools through the Corporate Social Responsibility (CSR) program of Santri Empowerment by building a Hydroponic Nutrition Garden at the Hidayatullah Islamic Boarding School, Depok, West Java.

Bandung, Jawa Barat / 15-16 Desember 2018 Bandung, West Java/ December 15-16, 2018

Rangkaian acara “Health and Beauty Fest 2018” dalam rangka Grand Launching varian produk Marcks’ dan Venus Cosmetics di Bandung, Jawa Barat.

The series of events “Health and Beauty Festival 2018” in Grand Launching of Marcks’ and Venus Cosmetics product variants in Bandung, West Java.

Depok, Jawa Barat / 17 Desember 2018Depok, West Java/ December 17, 2018

Laporan ManajemenManagement Report

Perseroan memiliki kewajiban moral yang tinggi untuk dapat mendukung program Pemerintah Indonesia dalam memberikan layanan kesehatan publik kepada masyarakat.

The Company has a high moral obligation to be able to support the Indonesian Government’s program in providing public health services to the public.

46


Laporan Dewan KomisarisBoard of Commissioners’s Report

Laporan Manajemen


Digital Farmasi sebagai terobosan Perseroan telah berhasil dibentuk dengan pengembangan Enterprise Resources Planning (ERP)

untuk dapat menunjang tranformasi tersebut.

Digital Pharmacy as a breakthrough of the Company has been successfully established with the development of Enterprise Resources Planning(ERP)

to support this transformation

Untung Suseno SutarjoKomisaris Utama

President Commissioner

47




Management Report

Company Profile






Management Report

Company Profile




Business Suppo

Documents

Enhancing Quality...This Annual Report contains financial statements, results of operations, policies, projections, plans, ... tentang tugas, peran, serta fungsi struktural organisasi